Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Briquilimab by Jasper Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Briquilimab is under clinical development by Jasper Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Data Insights
Briquilimab by Jasper Therapeutics for Chronic Urticaria Or Hives: Likelihood of Approval
Briquilimab is under clinical development by Jasper Therapeutics and currently in Phase II for Chronic Urticaria Or Hives. According to...